Safety Rates Drug Report: TYSABRI Invasive lobular breast carcinoma adverse events in 2016 Q3 - FDA prescription drugs adverse events in an open, searchable, online, public database

2004.Q1 2004.Q2 2004.Q3 2004.Q4 2005.Q1 2005.Q2 2005.Q3 2005.Q4 2006.Q1 2006.Q2 2006.Q3 2006.Q4 2007.Q1 2007.Q2 2007.Q3 2007.Q4 2008.Q1 2008.Q2 2008.Q3 2008.Q4 2009.Q1 2009.Q2 2009.Q3 2009.Q4 2010.Q1 2010.Q2 2010.Q3 2010.Q4 2011.Q1 2011.Q2 2011.Q3 2011.Q4 2012.Q1 2012.Q2 2012.Q3 2012.Q4 2013.Q1 2013.Q2 2013.Q3 2013.Q4 2014.Q1 2014.Q2 2014.Q3 2014.Q4 2015.Q1 2015.Q2 2015.Q3 2015.Q4 2016.Q1 2016.Q2 2016.Q3

Drug Injury Quarter

Drug: TYSABRI Injury: Invasive lobular breast carcinoma Quarter: 2016Q3

|< 1/2 << Previous Page Page 1

Total Records: 1 Number of Pages: 1

Event ID	DRUGNAME	PT	Drug Manufacturer	Patient Age	Sex	Weight	Date (YYYYMMDD)	Country
119205354	TYSABRI	Invasive lobular breast carcinoma	BIOGEN	52.75 YR	F	0	20160725	US

|< 1/2 << Previous Page Page 1

Total Records: 1 Number of Pages: 1

Execution Time: 0.11046886444092 seconds (ucode:5080076). Developed by: James D. Barger